PedAM
Pediatric Disease Annotations & Medicines
| Disease | hyperglycemia |
| Phenotype | C0011860|type 2 diabetes mellitus |
| Sentences | 28 |
| PubMedID- 25284699 | Glucagon-like peptide-1 receptor (glp-1) agonists and dipeptidyl-peptidase-4 (dpp-4) inhibitors are therapies that are used to treat hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 25317173 | Early macrovascular atherosclerosis may play a crucial role in subtle brain atrophy in type 2 diabetes mellitus patients, with chronic hyperglycemia playing a lesser role. |
| PubMedID- 24341330 | The persistent hyperglycemia in patients with type 2 diabetes mellitus is strongly associated with microvascular and macrovascular complications [1]. |
| PubMedID- 24857350 | Background: chorea is a common presenting feature of metabolic disorders, including nonketotic hyperglycemia in patients with type 2 diabetes mellitus, but rarely has been reported in diabetic ketoacidosis, hypothyroidism and vitamin b12 deficiency. |
| PubMedID- 23220949 | Effect of additional administration of acarbose on blood glucose fluctuations and postprandial hyperglycemia in patients with type 2 diabetes mellitus under treatment with alogliptin. |
| PubMedID- 24465132 | When contraindications to its use exist or patients cannot tolerate it due to adverse effects, clinicians have a variety of other classes of agents to treat hyperglycemia associated with type 2 diabetes mellitus. |
| PubMedID- 26253538 | Secondly, we sought to investigate the effect of glp-1 modulation on myocardial function in the setting of hyperglycemia in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 24444522 | The therapeutic armamentarium for the treatment of hyperglycemia in type 2 diabetes mellitus is still inadequate. |
| PubMedID- 23315305 | The clinical management of hyperglycemia in patients with type 2 diabetes mellitus (t2dm) is guided not only by published treatment algorithms, but also by consideration of recent evidence and through consultation with colleagues and experts. |
| PubMedID- 23816355 | Exercise has been widely recognized to ameliorate insulin resistance and hyperglycemia in individuals with type 2 diabetes mellitus (t2dm) [1,2]. |
| PubMedID- 20876838 | Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. |
| PubMedID- 23614630 | The position statement on the management of hyperglycemia in patients with type 2 diabetes mellitus issued in 2012 by the american diabetes association and the european association for the study of diabetes contains significant improvements over the 2009 version, including an emphasis on patient-centered care, enhanced strategies for lifestyle modification, a focus on comprehensive cardiovascular risk reduction, and increased pharmacotherapy choices. |
| PubMedID- 24516103 | Dipeptidyl peptidase-4 inhibitors prevent the degradation of incretin hormones and reduce postprandial hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 23231438 | In clinical trials, both exenatide formulations reduced hyperglycemia in patients with type 2 diabetes mellitus (t2dm) and were associated with weight loss. |
| PubMedID- 21046527 | Aleglitazar, being developed by roche holding, is a dual agonist for ppargamma and pparalpha for the potential simultaneous treatment of hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus (t2dm). |
| PubMedID- 24717767 | Abnormal regulation of glucagon secretion has been implicated in the development of hyperglycemia in patients with type 2 diabetes mellitus [16], and a recent study in animal models indicated that a reduction in glucagon action can have profound effects on mitigating hyperglycemia even in the presence of severe hypoinsulinemia [17]. |
| PubMedID- 25927597 | In recent years, selective sglt2 inhibitors have been developed and are now in clinical use for the treatment of hyperglycemia in patients with type 2 diabetes mellitus [19]. |
| PubMedID- 24741511 | [23161718] figure 1 summarizes the ada-easd recommended algorithm for the management of hyperglycemia in type 2 diabetes mellitus (t2d). |
| PubMedID- 22111038 | It is well established that chronic hyperglycemia in patients with type 2 diabetes mellitus causes progressive deterioration of β-cell function. |
| PubMedID- 21886908 | The purpose of the current study was to assess whether type 2 diabetes mellitus-induced hyperglycemia has an effect on the lipid profile and release of oxidative stress markers and inflammatory mediators in patients with non alcoholic fatty liver disease and normal liver function tests which may in turn lead to enhancing the pathogenicity of this liver disease. |
| PubMedID- 23617251 | Aims: it is necessary to evaluate glucose variability and postprandial hyperglycemia in patients with well-controlled type 2 diabetes mellitus because of the limitations associated with hemoglobin a1c (hba1c) measurements. |
| PubMedID- 23576884 | Background: the purpose of this paper is to review the efficacy, safety, and tolerability of linagliptin in the management of hyperglycemia in adults with type 2 diabetes mellitus. |
| PubMedID- 22238392 | Context: dapagliflozin, a selective sodium-glucose cotransporter 2 (sglt2) inhibitor, reduces hyperglycemia in patients with type 2 diabetes mellitus (t2dm) by increasing urinary glucose excretion, and weight loss is a consistent associated finding. |
| PubMedID- 24858947 | hyperglycemia resulting from type 2 diabetes mellitus (t2dm) is the main cause of diabetic complications such as retinopathy and neuropathy. |
| PubMedID- 26024569 | Purpose: although newer agents (dipeptidyl peptidase [dpp]-4 inhibitors and glucagon-like peptide [glp]-1 receptor agonists) are available for the treatment of hyperglycemia in patients with type 2 diabetes mellitus (t2dm), the impact of the availability of these agents on the use of second-generation sulfonylureas (sus) is unknown. |
| PubMedID- 25651730 | Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. |
| PubMedID- 22611498 | Endothelial dysfunction associated with insulin resistance appears to precede the development of overt hyperglycemia in patients with type 2 diabetes mellitus [100, 101]. |
| PubMedID- 21521130 | Introduction: in preliminary clinical studies, aleglitazar, a new dual ppar-alpha-gamma agonist, has been demonstrated to improve hyperglycemia and dyslipidemia in patients with type 2 diabetes mellitus. |
Page: 1